INTERVIEW: Raising Hyperhidrosis Awareness with Dr. David Pariser, MD (Pt. 1)
source: pixabay.com

INTERVIEW: Raising Hyperhidrosis Awareness with Dr. David Pariser, MD (Pt. 1)

Did you know that November is considered to be Hyperhidrosis Awareness Month? This awareness campaign is intended to share information about hyperhidrosis (a medical condition causing excessive and uncontrolled sweating),…

Continue Reading INTERVIEW: Raising Hyperhidrosis Awareness with Dr. David Pariser, MD (Pt. 1)
New Positive Data from Relapsing-Remitting Multiple Sclerosis Clinical Trial
source: unsplash.com

New Positive Data from Relapsing-Remitting Multiple Sclerosis Clinical Trial

According to a story from PR Newswire, Immunic, Inc., a biopharmaceutical company prioritizing the development of oral immunology medicines for the treatment of chronic inflammatory and autoimmune disorders, has reported…

Continue Reading New Positive Data from Relapsing-Remitting Multiple Sclerosis Clinical Trial
Two Studies Lead to Possible Therapeutic Approach for Neurodegenerative Diseases
source: pixabay.com

Two Studies Lead to Possible Therapeutic Approach for Neurodegenerative Diseases

  The loss of axons (nervous system wiring) has been responsible for various neurodegenerative diseases such as peripheral neuropathies, Parkinson’s disease, glaucoma, and amyotrophic lateral sclerosis (ALS). According to a…

Continue Reading Two Studies Lead to Possible Therapeutic Approach for Neurodegenerative Diseases
INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma
Courtesy of Omega

INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma

Mahesh Karande, the President and CEO of Omega Therapeutics, is incredibly passionate about epigenetics. And it shows: in the work that he and his team do, in the therapies they…

Continue Reading INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma
Cemiplimab Still Safe and Effective for cSCC, Study Shares
https://pixabay.com/en/vials-science-liquids-ionic-1781316/

Cemiplimab Still Safe and Effective for cSCC, Study Shares

  So far, the Phase 2 EMPOWER-CSCC-1 clinical study has evaluated cemiplimab (also known as Libtayo) in individuals with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). Data from…

Continue Reading Cemiplimab Still Safe and Effective for cSCC, Study Shares
Results of a Three-Year Study Support AUSTEDO to Treat Chorea Related to Huntington’s Disease
source: unsplash.com

Results of a Three-Year Study Support AUSTEDO to Treat Chorea Related to Huntington’s Disease

According to the National Institute of Neurological Disorders and Stroke, chorea is defined as involuntary movements that are caused by a neurological disorder. It is one of a group of…

Continue Reading Results of a Three-Year Study Support AUSTEDO to Treat Chorea Related to Huntington’s Disease
Positive Phase 1 Data Available on Sebetralstat for HAE
Photo courtesy of Towfiqu Barbhuiya on Unsplash

Positive Phase 1 Data Available on Sebetralstat for HAE

  According to a late October 2022 news release from pharmaceutical company KalVista Pharmaceuticals, Inc. (“KalVista”), the company released positive data from a Phase 1 study evaluating oral sebetralstat for…

Continue Reading Positive Phase 1 Data Available on Sebetralstat for HAE

Cutting-Edge Cystic Fibrosis Therapies Are Overpriced. This Campaign is Calling for Greater Access

In recent years, treatment options for cystic fibrosis, a rare disease, have increased significantly in number and in effectiveness. However, many of the most effective treatments, developed by Vertex Pharmaceuticals,…

Continue Reading Cutting-Edge Cystic Fibrosis Therapies Are Overpriced. This Campaign is Calling for Greater Access
INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)
Photo courtesy of Amolyt Pharma

INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)

Before you read on, make sure to check out Part 1 of our interview. In Part 1, we discussed Dr. Sumeray's background, what hypoparathyroidism is, and its symptoms and treatments. Today, we're…

Continue Reading INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 2)
First-Line Nivolumab Shows Significant Promise for Patients with cSCC
https://unsplash.com/photos/G6wVoIJY-iI

First-Line Nivolumab Shows Significant Promise for Patients with cSCC

Both Libtayo (cemiplimab) and Keytruda (pembrolizumab) have been shown to be beneficial treatment options for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). But could Opdivo (nivolumab)…

Continue Reading First-Line Nivolumab Shows Significant Promise for Patients with cSCC